4:24 PM
 | 
Apr 18, 2017
 |  BC Extra  |  Company News

Alpine finds public path through Nivalis

Immunology company Alpine Immune Sciences Inc. (Seattle, Wash.) and cystic fibrosis play Nivalis Therapeutics Inc. (NASDAQ:NVLS) said they will merge in an all-stock transaction. Upon the deal's close, expected in 3Q17, the combined company will retain Alpine's name and trade on NASDAQ under a new, as-yet-undetermined ticker.

Alpine CEO Mitchell Gold will lead the combined company. Gold, who was CEO of Dendreon Corp.,...

Read the full 315 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >